SFeDu
of.211, Gorgoko St., 88 
Rostov-on-Don
Russia
344002
+7 (863) 250-59-54
This email address is being protected from spambots. You need JavaScript enabled to view it.
te@sfedu.ru

TERRA ECONOMICUS

  • Home
  • Issues
  • 2023
  • No 3
  • The sovereignty of Russia in the area of pharmaceuticals: Challenges and opportunities

The sovereignty of Russia in the area of pharmaceuticals: Challenges and opportunities


TERRA ECONOMICUS, , Vol. 21 (no. 3),

Pharmaceutical colonialism remains a sustained global phenomenon in the modern world, with Russia being a part of this landscape for decades. Efforts by domestically focused governments in pharmaceutically reliant nations to eliminate dependence have yielded only localized effects that lack political sustainability. Attaining the stature of “Big Pharma” corporation proves consistently elusive. Our analysis has delineated three distinct sectors within Russia’s pharmaceutical industry: the official foreign sector (54%), a private “shadow” sector that obscures owners and controllers, both domestic and foreign (43%), and state-owned enterprises (up to 3%). The industry’s regulatory framework is fractured between Russia’s Ministry of Industry and Trade and the Ministry of Health, precluding the state’s effective role as a centralized producer and client. This fragmented system is insufficient as a crisis response tool, incapable of securing pharmaceutical sovereignty over the long term, even with available resources. In response to sanctions imposed on Russia, the state apparatus employs an inertia-based model to address diminished availability of specific foreign drugs in the domestic market, thereby effectively sustaining the industry’s strategic non-competitiveness. We also examine a mobilization-based scenario for pharmaceutical industry development, oriented toward civilian and defense applications. This approach envisions a vertically integrated corporate structure, independent of ownership form, with the proposed establishment of the state entity “Rospharma” endowed with extensive authority at its core.
Citation: Gusev A.B., Yurevich M.A. (2023). The sovereignty of Russia in the area of pharmaceuticals: Challenges and opportunities. Terra Economicus 21(3), 17–31 (in Russian). DOI: 10.18522/2073- 6606-2023-21-3-17-31
Acknowledgment: The research was supported by the state assignment of the Government of the Russian Federation to the Financial University for the year 2023 on the topic “Development of recommendations for ensuring economic growth in Russia under conditions of sanction restrictions” (VTК-GZ-PI-37-23). The authors thank E.V. Balatsky for comments and suggestions on the article that helped strengthen it.


Keywords: pharmaceutical sovereignty; industry mobilization; state corporation in pharmaceuticals; import substitution; medicinal drugs

JEL codes: I18, L52, L65

References:
  • Волгина Н.А. (2022). «Звеньевая» реструктуризация глобальных фармацевтических цепочек под влиянием пандемии COVID-19. Вестник МГИМО Университета 15(1), 126–142. [Volgina, N. (2022). “Link” restructuring of global pharmaceutical chains under the influence of the COVID-19 pandemic. Bulletin of MGIMO University 15(1), 126–142 (in Russian)]. DOI: 10.24833/2071-8160-2022-1-82-126-142
  • Губина М.А. (2019). Импортозамещение и/или экспортная ориентация: опыт фармацевтической промышленности Индии. Вестник Санкт-Петербургского университета. Экономика 35(2), 197–222. [Gubina, M. (2019). Import substitution and/or export orientation: The experience of the pharmaceutical industry in India. Bulletin of St. Petersburg University. Economics 35(2), 197–222 (in Russian)]. DOI: 10.21638/spbu05.2019.202
  • Гусев А.Б., Ширяев А.А. (2021). Болевые точки стратегического развития России. Journal of Economic Regulation 12(3), 6–25. [Gusev, A., Shiryaev, A. (2021). Pain points of Russia’s strategic development. Journal of Economic Regulation 12(3), 6–25 (in Russian)]. DOI: 10.17835/2078-5429.2021.12.3.006-025
  • Доржиева В.В. (2023). Стратегия новой индустриализации фармацевтической промышленности: национальные приоритеты и новые вызовы. Научные труды Вольного экономического общества России 240(2), 198–215. [Dorzhieva, V. (2023). Strategy of new industrialisation of the pharmaceutical industry: National priorities and new challenges. Scientific Proceedings of the Free Economic Society of Russia 240(2), 198–215 (in Russian)].
  • Иванова Н.И., Мамедьяров З.А. (2022). Специфика развития российской фармацевтической отрасли. Журнал Новой экономической ассоциации 53(1), 248–255. [Ivanova, N., Mamedyarov, Z. (2022). Specifics of the development of the Russian pharmaceutical industry. Journal of the New Economic Association 53(1), 248–255 (in Russian)]. DOI: 10.31737/2221-2264-2022-53-1-15
  • Мамедьяров З.А. (2017). Тенденции и перспективы российской фармацевтической отрасли и применимость мирового опыта. МИР (Модернизация. Инновации. Развитие) 8(4), 772–780. [Mamedyarov, Z. (2017). Trends and prospects of the Russian pharmaceutical industry and the applicability of global experience. MIR (Modernisation. Innovation. Development) 8(4), 772–780 (in Russian)]. DOI: 10.18184/2079-4665.2017.8.4.772-780
  • Мамедьяров З.А. (2022). Развитие науки и технологий: посткризисные оценки. Мировая экономика и международные отношения 66(5), 14–22. [Mamedyarov Z.A. (2022). Development of science and technology: post-crisis assessments. World Economy and International Relations 66(5), 14–22 (in Russian)]. DOI: 10.20542/0131-2227-2022-66-5-14-22
  • Налимов П.А., Руденко Д.Ю. (2015). Мировой фармацевтический рынок: полярность глобального здоровья. Всероссийский экономический журнал ЭКО 489(3), 116–128. [Nalimov, P., Rudenko, D. (2015). World pharmaceutical market: polarity of global health. All-Russian Economic Journal ECO 489(3), 116–128 (in Russian)].
  • Пылаева И.С., Подшивалова М.В., Подшивалов Д.В. (2022). Влияние пандемии COVID-19 на устойчивое развитие фармацевтических компаний России. Вопросы экономики (10), 86–112. [Pylaeva, I., Podshivalova, M., Podshivalov, D. (2022). Impact of COVID-19 pandemic on sustainable development of pharmaceutical companies in Russia. Voprosy Ekonomiki (10), 86–112 (in Russian)]. DOI: 10.32609/0042-8736-2022-10-86-112
  • Устюжанина Е.В., Дементьев В.Е., Евсюков С.Г. (2020). Проблемы распределения власти и экономической ренты в сетях создания стоимости. Экономика и математические методы 56(1), 5–17. [Ustyuzhanina, E., Dementiev, V., Evsyukov, S. (2020). Problems of power distribution and economic rent in value creation networks. Economics and Mathematical Methods 56(1), 5–17 (in Russian)]. DOI: 10.31857/S042473880008468-3
  • Binagwaho, A., Mathewos, K., Davis, S. (2021). Time for the ethical management of COVID-19 vaccines. The Lancet Global Health 9(8), e1169-e1171. DOI: 10.1016/S2214-109X(21)00180-7
  • Chaudhuri, S. (2016). Can foreign firms promote local production of pharmaceuticals in Africa? In: Making Medicines in Africa: The Political Economy of Industrializing for Local Health, pp. 103–121. DOI: 10.1007/978-1-137-54647-0_7
  • Cherian, J., Rahi, M., Singh, S., Reddy, S., Gupta, Y. et al. (2021). India’s road to independence in manufacturing active pharmaceutical ingredients: Focus on essential medicines. Economies 9(2), 71. DOI: 10.3390/economies9020071
  • Civaner, M. (2012). Sale strategies of pharmaceutical companies in a “pharmerging” country: The problems will not improve if the gaps remain. Health Policy 106(3), 225–232. DOI: 10.1016/j.healthpol.2012.05.006
  • Cowart, T., Rashi, T., Bock, G. (2023). Should pharma companies waive their COVID-19 vaccine patents? Alegal and ethical appraisal. Laws 12(3), 47. DOI: 10.3390/laws12030047
  • Dneprovskaya, I., Arakelova, I., Legenkova, N., Danilenko, E., Tikhonova, A. (2023). The prospects for the development of the domestic pharmaceutical industry in the context of import substitution. In: Anticrisis Approach to the Provision of the Environmental Sustainability of Economy, 43–51. DOI: 10.1007/978-981-99-2198-0_5
  • Dosi, G., Marengo, L., Staccioli, J., Virgillito, M. (2023). Big pharma and monopoly capitalism: a long-term view. Structural Change and Economic Dynamics 65, 15–35. DOI: 10.1016/j.strueco.2023.01.004
  • Gajbhiye, D., Choudhry, S., Goel, S. (2022). Changing Dynamics of Indian Pharmaceutical Sector: Opportunities and Challenges. Journal of Development Economics and Finance 3(1), 77–98. DOI: 10.46791/jdef.2022.v03i01.04
  • González Peña, O., López Zavala, M., Cabral Ruelas, H. (2021). Pharmaceuticals market, consumption trends and disease incidence are not driving the pharmaceutical research on water and wastewater. International Journal of Environmental Research and Public Health 18(5), 2532. DOI: 10.3390/ijerph18052532
  • Horner, R. (2021). Global value chains, import orientation, and the state: South Africa’s pharmaceutical industry. Journal of International Business Policy 5, 1–20. DOI: 10.1057/s42214-021-00103-y
  • Klarin, A., Ray, P. (2019). Political connections and strategic choices of emerging market firms: Case study of Russia’s pharmaceutical industry. International Journal of Emerging Markets 14(3), 410–435. DOI: 10.1108/IJOEM-05-2016-0138
  • Kumar, P., Tripathy, S., Dureja, H. (2015). Pharma emerging market’s scaning by look and feel of its opportunities and challenges. Applied Clinical Research, Clinical Trials and Regulatory Affairs 2(3), 115–122. DOI: 10.2174/2213476X03666151125220257
  • Nezhnikova, E., Maksimchuk, M. (2019). Pharmaceutical industry in Russia: Problems and prospects of development. RUDN Journal of Economics 27(1), 102–112. DOI: 10.22363/2313-2329-2019-27-1-102-112
  • Okereke, M., Essar, M. (2021). Time to boost COVID-19 vaccine manufacturing: The need for intellectual property waiver by big pharma. Ethics, Medicine, and Public Health 19, 100710. DOI: 10.1016/j.jemep.2021.100710
  • Pourraz, J. (2022). Making medicines in post-colonial Ghana: State policies, technology transfer and pharmaceuticals market. Social Science & Medicine 311, 115360. DOI: 10.1016/j.socscimed.2022.115360
  • Tannoury, M., Attieh, Z. (2017). The influence of emerging markets on the pharmaceutical industry. Current Therapeutic Research 86, 19–22. DOI: 10.1016/j.curtheres.2017.04.005
  • Volgina, N. (2022). Business models of big pharma in Russia: A pharmaceutical value chain perspective. RUDN Journal of Economics 30(1), 57–69. DOI: 10.22363/2313-2329-2022-30-1-57-69
Publisher: Southern Federal University
Founder: Southern Federal University
ISSN: 2073-6606